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Abstract: The majority of meningiomas are grade I, but some grade I tumours are clinically more
aggressive. Recent advances in the genetic study of meningiomas has allowed investigation into the
influence of genetics on the tumour microenvironment, which is important for tumorigenesis. We have
established that the endpoint genotyping method Kompetitive Allele Specific PCR (KASP™) is a fast,
reliable method for the screening of meningioma samples into different non-NF2 mutational groups
using a standard real-time PCR instrument. This genotyping method and four-colour flow cytometry
has enabled us to assess the variability in the largest immune cell infiltrate population, M2 macrophages
(CD45+HLA-DR+CD14+CD163+) in 42 meningioma samples, and to suggest that underlying genetics
is relevant. Further immunohistochemistry analysis comparing AKT1 E17K mutants to WHO
grade I NF2-negative samples showed significantly lower levels of CD163-positive activated M2
macrophages in meningiomas with mutated AKT1 E17K, signifying a more immunosuppressive
tumour microenvironment in NF2 meningiomas. Our data suggested that underlying tumour
genetics play a part in the development of the immune composition of the tumour microenvironment.
Stratifying meningiomas by mutational status and correlating this with their cellular composition
will aid in the development of new immunotherapies for patients.
Keywords: meningioma; M2 macrophage; genotype; AKT1 E17K; NF2; non-NF2
1. Introduction
Meningiomas arise from the meningeal layers surrounding the brain and spinal cord and are the
most common primary intracranial tumours, accounting for 36% of all primary central nervous system
tumours [1]. Although 70–80% of these tumours are considered to be benign (WHO grade I), 15–20%
atypical (WHO grade II) and approximately 5% anaplastic (WHO grade III), a significant proportion
of patients with any of the three meningioma grades will eventually relapse [2]. The histological
grading of meningiomas can be falsely reassuring as there can be discordance between the histology
and clinical behaviour, with some grade I tumours behaving in a more clinically aggressive manner.
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Combining recent genetic findings, including DNA methylation data [3], could lead to a potential
molecular classification that will be better at predicting patient outcomes [4,5]. Surgical resection with
adjuvant radiotherapy in grade II and III tumours (higher-grade meningiomas) remains the primary
treatment option, with no clinically efficacious drug treatment for the management of meningiomas
currently known [6].
Mutations or deletions on the Neurofibromin 2 (NF2) gene, which is located on the 22q12.2 locus
and encodes the tumour suppressor Merlin [7], cause approximately half of all sporadic meningiomas [8].
NF2 gene inactivation can occur with mutations in other genes on chromosome 22, such as the SW1/SNF
chromatin remodelling complex subunit, SMARCB1 [9–11], and it is frequently mutated in higher
grades with associated worse prognosis [12]. Meningiomas with non-mutated NF2 genes (collectively
known as non-NF2 meningiomas) have been reported to be caused by somatic driver mutations
in genes associated with tumorigenesis, such as Tumour necrosis factor receptor associated factor
(TRAF7), Krupple like factor 4 (KLF4), v-akt murine thymoma viral oncogene (AKT1) and smoothened
(SMO) [9,13]. Moreover, next-generation sequencing has also detected mutations in POLR2A, BAP1,
PIK3CA, AKT3 and FGFR3 [11,14–16]. These non-NF2 meningiomas represent approximately 40% of
mainly grade I sporadic meningiomas, with the other 15–20% of meningiomas containing presently
unknown genetic drivers of tumorigenesis [8,17]. Interestingly, meningioma mutations have been
shown to correlate with specific histological subtypes and anatomical location; however, the functional
effects of these point mutations on the tumour microenvironment are unknown. Meningiomas that
occur due to NF2 mutations tend to be transitional or fibroblastic, and are located in the convexity
or (lateral or posterior) skull base, whereas non-NF2 meningiomas are more medially located [18].
For example, AKT1-mutated tumours are found in the anterior skull base, are usually histologically
meningothelial or transitional in nature, and tend to recur more quickly [19]. Interestingly, NF2
mutations are enriched in higher-grade tumours [20].
The literature does suggest a more immunosuppressive environment in higher-grade
meningiomas [21–23]. Macrophages are the most abundant immune cell in the meningioma
microenvironment, with lower variable percentages of other immune filtrates such as T-, B- and
NK cells [24,25]. Macrophage numbers are higher in grades II and III [26,27], and greater numbers have
been associated with monosomy 22/del(22q) karyotype [21]. Although activated M2 macrophages have
not been assessed in meningiomas, other brain tumours such as gliomas [28], glioblastomas [29] and
numerous other disease models have been shown to produce signature cytokines such as TNF-alpha,
TGF-beta, IL-6 and IL-10 [30–32].
The oncogene AKT1 has only one known hotspot, AKT1 E17K (c.49G>A; p.Glu17Lys), where
the mutation in the pleckstrin homology domain causes constitutive AKT1 activation, enhancing cell
proliferation and tumour growth [33]. This mutation is present in 8% of all meningiomas, but is also
observed in numerous other solid tumours, including approximately 3.5% of breast cancers, 3% of
endometrial cancers and 1.5% of ovarian cancers (COSMIC database v90 [34]). To our knowledge,
macrophage populations in AKT1 E17K-mutated meningiomas and other cancers have not been studied
to date, although it is known that the PI3K/AKT/mTOR pathway regulates macrophage biology [35].
In this study, we screened 171 meningiomas using endpoint genotyping and linked mutations
in AKT1 E17K and NF2 in grade I meningiomas to macrophage infilitration using four-colour flow
cytometry and immunohistochemistry. Our data suggest that the underlying genetics of the tumours
play a part in development of the immune composition of the tumour microenvironment.
2. Results
2.1. Mutational Hotspots were Detected at the Predicted Frequencies
We screened fresh meningioma samples prospectively using an endpoint genotyping method
to aid the stratification of our research into different genetic subgroups. Kompetitive Allele Specific
PCR (KASP™) is a fluorescence-based genotyping method which can bi-allelically score any known
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single-point DNA variant and small insertions or deletions (indels) using a standard real-time PCR
instrument available in most research and clinical laboratories.
A total of 171 meningiomas were screened using a KASP™ genotyping panel containing the
following somatic coding mutations: AKT1 E17K, KLF4 K409Q, PIK3CA E545K, PIK3CA H1047R,
POLR2A Q403K, POLR2A L438-H439del, SMARCB1 R374Q, SMARCB1 R377H, SMO L412F and SMO
W535L (Table 1). Due to the complex nature of NF2 loss by pathogenic single mutations occurring
across all exons or partial/complete deletions of the NF2 gene, KASP™ genotyping was not suitable.
Next-generation sequencing and multiplex ligation-dependent probe amplification were used on a
small number of tumours to validate loss of the Merlin (NF2) protein by Western blotting [36]. NF2
status was then assessed by either intact Merlin protein (non-NF2 meningiomas) or Merlin loss (NF2
meningiomas).
Table 1. Mutational frequencies detected by endpoint genotyping.
Gene Mutated/Total Detected Frequency % Frequency in Clark et al., 2016 b %
NF2 (protein loss) a 49/113 43.4 33.4
AKT1 E17K 10/159 6.3 10.6
KLF4 K409Q 12/158 7.6 7.9
PIK3CA H1047R 2/94 2.1 1.5
POLR2A Q403K 3/168 1.8 2.5
SMARCB1 R377H 1/139 0.7 Not reported
SMO L412F 3/150 2.0 3.2
No PIK3CA E545K (0/95), POLR2A L438-H439del (0/123), SMARCB1 R374Q (0/140), SMO W535L (0/163) mutations
were detected in any of the samples screened. a—NF2 loss was assessed by Western blot. b—Expected frequencies
taken from 775 meningiomas screened by Clark et al., 2016 [11].
Sanger sequencing was used to validate heterozygous mutations in the AKT1 and KLF4 genes
identified by KASP genotyping (Supplementary Table S1). We also confirmed by sequencing that
all AKT1 E17K mutants tested contained co-mutations in the WD40 region of the TRAF7 gene.
Our genotyping data displayed similar mutational frequencies to those described by Clark et al. in
2016 [11]. The slight differences in frequency may have been a reflection of our relatively small sample
size (Table 1). Half of our non-NF2 meningiomas (NF2-positive by Western blotting) contained no
detectable mutations according to our genotyping screening, and further in-depth sequencing analysis
is required, which is in agreement with the published literature [8].
2.2. Correlation of Genomic Subgroup with Clinical Characteristics
In agreement with current literature, there was a higher incidence of meningioma in female patients
(76%), but 30% of the male patients harboured the more aggressive form of the tumour [20]. The median
age of the patients in this study was 59 years. Previous publications have described associations
between driver mutations for meningiomas, their intracranial location and histological subtype. These
include the propensity for NF2 tumours to be located in the posterior fossa while non-NF2 tumours
tend to be located in the anterior or middle cranial fossae, and AKT1 E17K/TRAF7-mutant meningiomas
commonly being of meningothelial or transitional histological subtypes while the KLF4-K409Q mutant
tumours are often of the secretory subtype. In our dataset of tumours, all the SMO L412F mutant
tumours were observed exclusively as convexity supratentorial tumours and meningothelial subtypes,
while the PIK3CA H1047R mutant tumours were sphenoid wing meningiomas. The vast majority of
our non-NF2 mutant tumours occurred in female patients, and all these tumours were WHO grade I
tumours (Supplementary Table S1). In summary, our results confirmed that KASP™ genotyping is a
cheap, fast, robust method for the detection of known common non-NF2 mutations.
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2.3. Detection of M2 Macrophages by Four-Colour Flow Cytometry
Domingues et al. [26] clearly demonstrated that it is possible to detect tumour-associated
macrophages in single-cell suspensions using mechanical disaggregation by multicolour flow cytometric
immunophenotyping, and we therefore decided to use this technique to quantify the immune
infiltrates in our well established primary cell culture model [37] and to correlate these results to
mutational hotspots.
Initially, we assessed the CD4+ T cells, CD8+ T cells, CD19+ B cells, and CD14+ monocytes within
the CD45+ lymphocyte population. Although the percentage of CD45+ immune cells varied noticeably
in individual tumours, CD14+ monocyte cells were the most dominant population within all tumours,
representing over 90% of the CD45-positive immune infiltrate in samples tested (Supplementary
Table S2). Using the M2 macrophage marker CD163, we determined that the majority of the CD14+
monocytes were CD163-positive. We showed that CD163 protein expression was high in Passage 0 by
Western blotting, and this decreased over passages (Figure 1). In accordance with these data, flow
cytometry results also showed a decrease in the percentage of CD45+HLA-DR+CD14+CD163+ cells by
a similar amount during subsequent culture passages (Figure 1; Supplementary Figure S1).
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Next, we analysed 42 meningioma samples for both M2 macrophages
(CD45+HLA-DR+CD14+CD163+) and tumour cells (CD45−HLA−DR−CD14−CD44+) at Passage 0,
and related these results to mutational status. The percentage of M2 macrophages was very variable
from 0% to 75% with a median of 5%. These results were complemented by assessing the percentage
Int. J. Mol. Sci. 2020, 21, 1273 5 of 16
of tumour cells at the same time point, which varied from 25% to 97% with a median of 88.7%
(Supplementary Table S2). Focussing on WHO grade I meningiomas with different defined genotypes,
NF2 meningiomas displayed a tendency towards higher M2 macrophage infiltrates when compared to
AKT1 E17K-mutated tumours (Figure 2).
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Figure 2. (a) Representative flow cytometry dot plot for 14-PerCP-Cy5.5+ (FL3) CD163-AF647+
(FL4) cells in AKT1 E17K and NF2-negative primary cell culture at Passage 0 (p0) (b) Comparison of
the CD45+HLA-DR+CD14+CD163+ M2 macrophages in AKT1 E17K mutants (n = 4) and WHO grade I
NF2 negative meningiomas (n = 11). Line represents the median, ns = not significant.
2.4. Confirmation of Macrophage Levels Using Immunohistochemistry
Next, we decided to confirm by immunohistochemistry the flow cytometry results at Passage
0, which showed that genotype could have some influence on the immune microenvironment (IHC).
In total, we carried out staining on 20 meningiomas (11 non-NF2 vs. 9 NF2) using the macrophage
markers CD68 (pan), CD86 (M1), CD163 (M2) and CD206 (M2). In general, the CD86 M1 macrophage
marker was of weak staining intensity in all non-NF2 and NF2 cases. CD163-positive M2 macrophages
were identified in all cases and at variable levels (range: 3.5–23.1%; median: 9.7%) confirming our
flow cytometry data. Both methods were carried out in the same tumours, but the percentage of
CD163-positive cells detected by four-colour flow cytometry analysis did not correlate directly to the
number detected by IHC. The percentage of CD163-positive cells detected by IHC related well with
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the pan-macrophage marker CD68 (range: 2.3–18.5%; median: 9.4%) and another M2 macrophage
marker, CD206 (Supplementary Table S2). These results were in agreement with recently published
data reporting that the majority of tissue-associated macrophages in meningiomas are M2 macrophages
with high CD163/CD206 staining and low CD80/CD86 staining [27].
Comparing the AKT1 E17K tumour tissues to the NF2-negative grade I meningiomas showed
that AKT1 E17K mutants contained significantly fewer CD68 macrophages (7.4 vs. 10.7%; p = 0.036;
Figure 3) and CD163-positive cells (8.4 vs. 12.9%; p = 0.049; Figure 4) compared to NF2 meningiomas,
supporting the flow cytometry data suggesting that genotype may influence immune cell filtration
over the course of tumour development.
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Figure 3. (a) Representative immunohistochemistry images for CD68-stained macrophages in AKT1
E17K- and NF2-negative meningiomas, ×100 magnification (b) % of CD68+ cells in AKT1 E17K mutants
(n = 7) compared to WHO grade I NF2-negative (n = 6) meningiomas by IHC; line represents the
median, * p < 0.05.
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Figure 4. (a) Representative immunohistochemistry images for CD163-stained macrophages in AKT1 
E17K- and NF2-negative meningioma (MN) tissue sections, ×100 magnification (b) % of CD163+ cells 
in AKT1 E17K mutants (n = 7) compared to WHO grade I NF2-negative (n = 6) meningiomas by IHC; 
line represents the median, * p < 0.05. 
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To better understand whether the higher levels of M2 macrophages observed in the NF2-
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cytokines shown to be relevant in M2 macrophage polarization. Comparison of the AKT1 E17K and 
NF2-negative mRNA expression levels determined that IL-10 mRNA was significantly elevated in 
the grade I NF2 negative meningioma tissues (Figure 5). Collectively, results suggest that M2 
Figure 4. (a) Representative immunohistochemistry images for CD163-stained macrophages in AKT1
E17K- and NF2-negative eningioma (MN) tissue sections, ×100 magnification (b) % of CD163+ cells
in AKT1 E17K mutants ( = 7) compared to WHO grade I NF2-negative (n = 6) meningiomas by IHC;
line represents the median, * p < 0.05.
2.5. Assessment of Cytokine mRNA Expression Associated with Activated M2 Macrophages
To better understand whether the higher levels of M2 macrophages observed in the NF2-negative
grade I meningiomas were activated, we conducted gene expression analysis of four key cytokines
shown to be relevant in M2 macrophage polarization. Comparison of the AKT1 E17K and NF2-negative
mRNA expression levels determined that IL-10 mRNA was significantly elevated in the grade I NF2
negative meningioma tissues (Figure 5). Collectively, results suggest that M2 macrophages are activated
in grade I tumour tissue although, due to the variability in the expression levels for IL-6, TGF-beta and
TNF-alpha in individual samples, these results were not significant.
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3. Discussion
Using our rapid KASP™ genotyping technique and flow cytometry to directly analyse immune
infiltrates after tissue dissociation has allowed us to assess larger numbers of tumours quicker and
more quantifiably than was previously possible with immunohistochemistry alone.
Loss of NF2 function or loss of heterozygosity at chromosome 22q, where NF2 is located, has been
linked to sporadic higher grade meningiomas and poor prognosis [12,38]. The actual effect of NF2
loss on cell populations within a tumour is not known, although the literature does indicate a more
immunosuppressive environment in higher grades [21–23]. We showed that AKT1 E17K-mutated
meningiomas have a less immunosuppressive tumour microenvironment when compared to grade I
NF2 meningiomas; this may explain why some NF2 tumours have high progression/recurrence rates.
The molecular mechanism of how AKT1 E17K or NF2 loss influences immunosuppressive environment
in the tumour is likely to involve different cell types and be more complex [39]. However, to our
knowledge, this is the first time that differences in M2 macrophages in grade I meningiomas have been
linked to driver mutations, and could potentially help in developing directed immunotherapies in
genetically stratified meningioma patients.
Pinton et al. [22] also observed over 60% lymphocytes (CD45+ cells) in fresh tumour cell suspensions
using multicolour flow cytometry in 2018, with myeloid cells CD33+ HLA-DR+ representing the largest
population (80.4% +/− 20.6%) of the CD45+ group, which was in agreement with our results. Recently,
non-progressing grade I meningiomas have been shown to have noticeably higher levels of CD45+
inflammatory cells compared to grade II/ III meningiomas [23]. Although these results were not linked
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to mutational status, they do indicate that immune filtrates play a key role in tumorigenesis, and future
detailed studies linking genotype to the tumour microenvironment are warranted.
Variable levels of infiltrating tissue macrophages in meningioma have been previously reported.
CD163 is a well-established M2 macrophage marker and has previously been shown using
immunohistochemistry to be in high abundance in atypical grade II meningiomas [27,40] but, unlike
previous authors, we correlated CD68 (Figure 3) and CD163 expression with NF2 status (Figure 4).
Our short-term cell culture data were corroborated by IHC analysis. However, within our dataset we
were unable to directly correlate IHC and flow cytometry results for CD163 expression in individual
tumours (Supplementary Table S2), which was in agreement with previous literature [41]. Importantly,
however, both methods showed that M2 macrophages were higher in NF2-negative tumours by
similar relative ratios. Thus, different methods within themselves are consistent. We did not polarise
macrophages in our short-term cell culture technique; sample handling may therefore have led to
activation of HLA class II of certain populations and could, along with the difference in techniques
(surface expression versus cell cross section) explain discrepancies in sensitivity between techniques.
Additionally, we used the cell adhesion molecule CD44, previously shown to be expressed on
meningioma tumour cells [42,43], to support the large variation in immune filtrates by gating tumour
cells (CD45−HLA-DR−CD14−CD44+) at each time point.
High CD163 levels have recently been suggested to be a potential biomarker for poor prognosis in
a number of solid tumours, including gliomas [44], oestrogen-receptor-positive breast cancer [45] and
head and neck squamous cell carcinomas [46]. A major role of macrophages is the clearance of apoptotic
cells (efferocytosis), which in the context of cancer is tumour-promoting, inducing a wound-healing
immunosuppressive environment. M2 macrophages have a greater capacity for efferocytosis than M1
macrophages, which could explain why higher CD163 levels correlate with poor prognosis in some
tumours [47], although, due to the plasticity of tumour-associated macrophages, high M2 macrophage
infiltrates do not predict poor overall survival in all cancers [30]. To further support the notion that the
CD163-labelled M2 macrophages were activated, we showed expression of IL-10, TNF-α, TGF-β1 and
IL-6 in all tumour tissues. Significantly, the key signature cytokine IL-10, known to be produced by all
M2 macrophage phenotypes [32], was nearly four-fold higher in the NF2-negative tumours.
Microglia make up 75% of the distinct central nervous system (CNS) immune cell population
located in the parenchyma and border areas of the central nervous system. It was previously believed
that tumour-associated microglia and tumour-associated bone-derived macrophages exert similar
functions in brain tumours; however, recent gene expression analysis in glioblastoma (GBM) revealed
that microglia are associated with housekeeping functions such as inducing a pro-inflammatory
response, and macrophages are associated with wound healing and immune suppression [48].
Therefore, future work examining the ratio of tumour-associated microglia to macrophages using gene
expression signatures in meningiomas and relating this ratio to genotype would be of great interest.
The immune checkpoint marker PD-L1 has been shown to increase in anaplastic
meningiomas [49], suggesting that higher-grade tumours harbour a more immunosuppressive tumour
microenvironment [50], although immune therapy targeting PD-L1 in meningiomas may be limited
due to expression levels [51,52]. Recently, lower proportions of PD-1 positive cytotoxic T cells
(CD3+CD8+FOXP3−) have been associated with poorer survival, with longitudinal analyses of the
tumour-infiltrating T-lymphocytes suggesting large changes in the microenvironment over the course
of the disease [25]. Erkan et al. [53] highlighted in 2019 the importance of an equilibrium between
tumour-promoting and anti-immunity pathways in the blood of grade I meningioma patients using a
multiplex immunoassay cancer panel, suggesting that progressing grade I meningioma patients may
benefit from immunotherapeutic options.
Proctor et al. [51] also recently linked mutations in the PI3K/AKT/mTOR pathway to elevated
levels of the immune checkpoint proteins PD-L2 and B7-H3, strengthening the evidence that genetic
changes can stimulate a different tumour microenvironment. The impact of somatic alternations
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on immune responses has previously been shown in BRAF mutations in melanoma [54] and IDH
mutations in glioma [55].
In conclusion, although the literature concerning immune cells in meningiomas is less extensive
than for other brain tumours such as gliomas, it is highly probable that macrophages play an important
role in the growth and progression of meningothelial neoplasms [24]. Future work is required to
elucidate the role of M2 macrophages in meningiomas, and to uncover the mechanisms in which tumour
cells harbouring a mutation such as AKT1 E17K can directly affect the tumour microenvironment.
From proteomics studies [36,37] published by our group and others, it is clear that the tumour
microenvironment of meningiomas is highly heterogeneous, and that linking cell population, gene
expression and/or signalling pathway activation data to genetically defined non-NF2 and NF2 groups
would be very beneficial. The simple, cost-effective endpoint genotyping technique used here could
aid such stratification in any research or clinical laboratory with a real-time PCR instrument.
4. Methods and Materials
4.1. Clinical Samples
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was granted
full national ethics approval (Approval Date: 20 May 2014) by the South West research ethics committee
(REC no: 14/SW/0119; IRAS project ID: 153351), as well as local research and development approval
(Plymouth Hospitals NHS Trust: R&D No: 14/P/056 and North Bristol NHS Trust: R&D No: 3458;
Approval Date: 18 May 2015). Meningioma MN specimens were collected after planned surgical
procedures when surplus tissue was available.
Meningioma SS specimens were collected via UK Brain Archive Information Network (BRAIN
UK; https://www.southampton.ac.uk/brainuk/index.page) application “A pilot study analyzing the
effect of driver mutations on the (phospho)proteome and microenvironment of meningiomas (Ref no:
15/011)”. BRAIN UK was granted full Health Research Authority approval (Approval Date: 21 July
2015) by the South Central NRES committee (REC no: 14/SC/0098).
4.2. End Point Genotyping Method
The samples were cut off excess tumour after diagnostic testing, snap-frozen in liquid nitrogen
and then conserved at −20 ◦C. DNA extraction was performed using the DNeasy kit and blood and
tissue miniprep kit (QIAGEN, Manchester, UK), and DNA concentrations were then calculated using
Thermofisher Scientific Nanodrop 2000 (Waltham, MA, USA). Endpoint genotyping (Kompetitive
Allele Specific PCR (KASP™ [56]) was performed on a Roche Life Sciences Light Cycler 480 II (West
Sussex, UK). Oligonucleotides were designed using the genomic reference sequence for each gene.
Reactions were carried out in a final volume of 10 µL consisting of genomic DNA (40 ng/µL), 2× KASP
low ROX mix and a primer mix containing two allele-specific forward primers and a common reverse
primer (Supplementary Table S3; LGC Genomics Ltd., Hertfordshire, UK). Synthetic gene fragments
containing known heterozygous or homozygous mutations (gBlocks; Integrated DNA Technologies,
Leuven, Belgium) were used as positive controls to aid visualization via Cartesian plots.
4.3. Sanger Sequencing
PCR and sequencing primers were designed using the genomic reference sequences and the
bioinformatics program Unipro Ugene version 33 (http://ugene.net/download.html). PCR conditions
were optimised (Supplementary Table S3) and products were run on 1.2% agarose gels, cleaned up
using the Monarch PCR & DNA cleanup kit (New England Biolabs, Ipswich, MN, USA) and sent to
Eurofins, Ebersberg, Germany) for Sanger sequencing.
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4.4. Western Blotting
Cells were lysed in RIPA buffer with protease and phosphatase inhibitors (cocktail tablets, Roche
and phosphatase inhibitor cocktail B and C, Santa Cruz Biotechnology, Heidelberg, Germany). Protein
concentrations were estimated using the Pierce™ BCA Protein Assay Kit (ThermoFisher Scientific,
Waltham, MA, USA), following the instructions of the supplier. Proteins were separated on a 10%
Laemmli SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Immun-Blot® PVDF
Membrane, Bio-Rad, Watford Hertfordshire, UK). Membrane blocking, antibody incubation and washes
were performed as previously described (Supplementary Table S4) [37]. Detection was achieved using
the Pierce ECL or ECL Plus Western Blotting substrate (Thermo scientific). Membranes were exposed
to Amersham Hyperfilm ECL (GE Healthcare Life Sciences, Amersham, UK). Immunoreactive bands
were quantified using Image J software (www.https://imagej.nih.gov/ij/index.html) and each band was
normalised to the corresponding GAPDH.
4.5. Isolation of Primary Meningioma Cells from Fresh Tissue
Fresh tumour samples were transferred into a sterile tube containing transportation medium
(DMEM supplemented with 10% FBS, 500 U/mL penicillin and streptomycin, 2.5 µg/mL amphotericin
B). The meningioma were washed twice with sterile PBS and transferred into incubation medium
(DMEM supplemented with 10% FBS, 100 U/mL penicillin and streptomycin). Digestion medium
consisted of DMEM supplemented with 10% FBS, 100 U/mL penicillin and streptomycin, and 20
units/mL of Type III collagenase (Worthington Biochemical Corp, Lakewood Township, NJ, USA)
was added to the plate and incubated at 37 ◦C overnight. The day after, the meningiomas were
mechanically digested and centrifuged at 1500 rpm for 5 min [57]. Cells were seeded into flasks
containing meningioma medium (DMEM supplemented with 10% FBS, 1% glutamax, 1% glucose,
100 U/mL penicillin and streptomycin) and incubated at 37 ◦C in a humidified atmosphere (5% CO2).
Confluent cultures were split using 0.05% trypsin/EDTA, and medium was changed twice a week.
4.6. Flow Cytometry
Primary meningioma cells were washed once in ice-cold flow-staining buffer (PBS, 2% FBS; filter
sterilised) and resuspended in flow-staining buffer at a final concentration of 5 × 105 cells. Cells were
labelled with the antibodies outlined in Supplementary Table S4 (all from Becton Dickinson (BD)
Biosciences, Pharmigen, Wokingham, UK), incubated in the dark at room temperature for 30 min,
washed twice and resuspended in ice-cold staining buffer. Relevant single isotype controls were
used. Data were collected on 1 × 104 cells per antibody combination on an Accuri flow cytometer
(BD Biosciences) and analysis was performed using the Flow Jo software version 10.0 (Lake Oswego,
OR, USA).
4.7. Immunohistochemistry
Paraffin sections (4 µm) were de-waxed, rehydrated and incubated with primary antibody
(Supplementary Table S4) at room temperature O/N after antigen retrieval in Tris/EDTA for 30 min [58].
Proteins were visualised using 3,3′-diaminobenzidine (DAB) and counterstained with haematoxylin
(Sigma-Aldrich, Dorset, UK). The immunohistochemical results were reviewed by a neuropathologist
(DAH) blinded to the histological grade. Semi-quantitative assessment of staining intensity was
assigned as follows: 0 (negative), 1 (low), 2 (moderate) and 3 (strong). Scoring intensity (% of positive
cells: a single ×100 image taken and the area fraction stained within this field, also measured using
image analysis).
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4.8. Quantitative Real-Time PCR Analysis
Total RNA was extracted from fresh frozen tissue using the Qiazol® reagent (Qiagen, UK),
following the manufacturer’s protocol. The quality and concentration of RNA was established using
the NanoDrop 2000) Reverse transcription and real-time PCR was performed on 700 ng of total RNA as
previously described [59]. Primers were designed against the reference coding sequence (CDS) for each
gene (Supplementary Table S3). GapDH gene was used as internal control, all analyses were performed
with three replicates and relative gene expression levels were computed using the quantitative 2−(∆∆Ct)
method, employing normal meninges tissue as a calibrator [60].
4.9. Statistical Analysis
Statistical analysis was performed using the unpaired Student’s t-test performed using GraphPad
Prism (https://www.graphpad.com/scientific-software/prism/). A significance level of p < 0.05 was
considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/4/1273/s1.
Figure S1—Flow cytometry gating strategy, Table S1—Genotyped samples, Table S2—Macrophage data, Table
S3—Olignonucleotide details, Table S4—Antibody details.
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